U.S. markets closed

Ekso Bionics Holdings, Inc. (EKSO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.15-0.01 (-0.14%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close7.16
Bid7.12 x 1200
Ask7.21 x 2900
Day's Range6.50 - 7.39
52 Week Range2.25 - 14.98
Avg. Volume383,967
Market Cap87.364M
Beta (5Y Monthly)2.20
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Recap: Ekso Bionics Holdings Q4 Earnings

    Shares of Ekso Bionics Holdings (NASDAQ:EKSO) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 1100.00% over the past year to ($0.48), which missed the estimate of ($0.30). Revenue of $2,254,000 decreased by 39.39% from the same period last year, which missed the estimate of $2,580,000. Outlook Earnings guidance hasn't been issued by the company for now. Ekso Bionics Holdings hasn't issued any revenue guidance for the time being. How To Listen To The Conference Call Date: Feb 25, 2021 View more earnings on EKSO Time: 04:30 PM ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/ekso/mediaframe/43125/indexl.html Technicals Company's 52-week high was at $14.98 52-week low: $0.15 Price action over last quarter: Up 100.74% Company Profile Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. See more from BenzingaClick here for options trades from BenzingaEarnings Preview: Ekso Bionics Holdings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Benzinga

    Earnings Preview: Ekso Bionics Holdings

    On Thursday, February 25, Ekso Bionics Holdings (NASDAQ:EKSO) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. What Are Earnings, Net Income, And Earnings Per Share? Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS. Earnings And Revenue Analysts are predicting Ekso Bionics Holdings will report a loss of $0.3 per share on revenue of $2.58 million. Ekso Bionics Holdings EPS in the same period a year ago totaled $0.04. Sales were $3.72 million. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values. View more earnings on EKSO If the company were to match the consensus estimate when it reports Thursday, EPS would have fallen 650.0%. Revenue would have fallen 30.63% from the same quarter last year. Here is how the company's reported EPS has stacked up against analyst estimates in the past: Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020 EPS Estimate -0.39 -0.55 -0.61 -0.04 EPS Actual -0.32 -1.84 -0.44 -0.04 Revenue Estimate 2.45 M 1.62 M 1.41 M 3.65 M Revenue Actual 2.90 M 2.30 M 1.47 M 3.72 M Stock Performance Over the last 52-week period, shares are up 60.39%. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement. Do not be surprised to see the stock move on comments made during its conference call. Ekso Bionics Holdings is scheduled to hold the call at 16:30:00 ET and can be accessed here. See more from BenzingaClick here for options trades from BenzingaEx-Dividend Date Insight: Ashland Global HoldingsEx-Dividend Date Insight: Voya Finl© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Ekso Bionics Holdings' (NASDAQ:EKSO) Shareholders Are Down 89% On Their Shares
    Simply Wall St.

    Ekso Bionics Holdings' (NASDAQ:EKSO) Shareholders Are Down 89% On Their Shares

    It is doubtless a positive to see that the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has gained some 124...